About midostaurin
Kinase inhibitor; antineoplastic
Used for
- Treats newly diagnosed FLT3-mutated acute myeloid leukemia with chemotherapy.
- Treats advanced systemic mastocytosis, including aggressive disease and mast cell leukemia.
Usual adult dose
AML: 50 mg twice daily on days 8–21 of chemotherapy cycles. Systemic mastocytosis: 100 mg twice daily.
Common side effects
- Nausea, vomiting, diarrhea, or abdominal pain
- Low blood counts, bruising, or infections
- Swelling, fatigue, or headache
- Lung inflammation or breathing difficulty
Important warnings
- Can cause serious lung inflammation; urgent assessment is needed for new breathing problems.
- May harm an unborn baby; pregnancy testing and effective contraception are recommended.
- Can cause QT prolongation; monitoring may be needed, especially with heart risks.
- Strong CYP3A4 inhibitors or inducers can substantially change midostaurin levels.
Pregnancy
May cause fetal harm. Avoid during treatment and for four months after the last dose; effective contraception is recommended.
Breastfeeding
Do not breastfeed during treatment and for four months after the last dose.
Interactions
- Strong CYP3A4 inhibitors, such as clarithromycin or ketoconazole, may raise drug levels.
- Strong CYP3A4 inducers, such as rifampin or St John’s wort, may lower drug levels.
- May affect medicines processed by CYP3A4, including some hormonal contraceptives.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.